The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Long-Acting Injectables Market Research Report 2025
Synopsis
Long-acting injectable (LAI) is a kind of pharmaceutical for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication. Rather than the daily pill-taking required with oral antipsychotics, LAI antipsychotics are administered by injection at two to four weeks intervals.
The global Long-Acting Injectables market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Long-Acting Injectables is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-Acting Injectables is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Long-Acting Injectables in Schizophrenia is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Long-Acting Injectables include Eli Lilly, Pfizer, GlaxoSmithKline, Johnson & Johnson, Lupin, Zogenix, DURECT and Medincel, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Injectables.
Report Scope
The Long-Acting Injectables market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-Acting Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Pfizer
GlaxoSmithKline
Johnson & Johnson
Lupin
Zogenix
DURECT
Medincel
Segment by Type
Small and Middle Sized Molecule
Large Sized Molecule
Segment by Application
Schizophrenia
Other Psychotic Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Long-acting injectable (LAI) is a kind of pharmaceutical for treating patients with schizophrenia who relapse due to nonadherence to antipsychotic medication. Rather than the daily pill-taking required with oral antipsychotics, LAI antipsychotics are administered by injection at two to four weeks intervals.
The global Long-Acting Injectables market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Long-Acting Injectables is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Long-Acting Injectables is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Long-Acting Injectables in Schizophrenia is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Long-Acting Injectables include Eli Lilly, Pfizer, GlaxoSmithKline, Johnson & Johnson, Lupin, Zogenix, DURECT and Medincel, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Long-Acting Injectables, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Long-Acting Injectables.
Report Scope
The Long-Acting Injectables market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Long-Acting Injectables market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Long-Acting Injectables companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Pfizer
GlaxoSmithKline
Johnson & Johnson
Lupin
Zogenix
DURECT
Medincel
Segment by Type
Small and Middle Sized Molecule
Large Sized Molecule
Segment by Application
Schizophrenia
Other Psychotic Disorders
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Long-Acting Injectables companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Long-Acting Injectables Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Small and Middle Sized Molecule
1.2.3 Large Sized Molecule
1.3 Market by Application
1.3.1 Global Long-Acting Injectables Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Schizophrenia
1.3.3 Other Psychotic Disorders
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Long-Acting Injectables Market Perspective (2019-2030)
2.2 Long-Acting Injectables Growth Trends by Region
2.2.1 Global Long-Acting Injectables Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Long-Acting Injectables Historic Market Size by Region (2019-2024)
2.2.3 Long-Acting Injectables Forecasted Market Size by Region (2025-2030)
2.3 Long-Acting Injectables Market Dynamics
2.3.1 Long-Acting Injectables Industry Trends
2.3.2 Long-Acting Injectables Market Drivers
2.3.3 Long-Acting Injectables Market Challenges
2.3.4 Long-Acting Injectables Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Long-Acting Injectables Players by Revenue
3.1.1 Global Top Long-Acting Injectables Players by Revenue (2019-2024)
3.1.2 Global Long-Acting Injectables Revenue Market Share by Players (2019-2024)
3.2 Global Long-Acting Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Long-Acting Injectables Revenue
3.4 Global Long-Acting Injectables Market Concentration Ratio
3.4.1 Global Long-Acting Injectables Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Long-Acting Injectables Revenue in 2023
3.5 Long-Acting Injectables Key Players Head office and Area Served
3.6 Key Players Long-Acting Injectables Product Solution and Service
3.7 Date of Enter into Long-Acting Injectables Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Long-Acting Injectables Breakdown Data by Type
4.1 Global Long-Acting Injectables Historic Market Size by Type (2019-2024)
4.2 Global Long-Acting Injectables Forecasted Market Size by Type (2025-2030)
5 Long-Acting Injectables Breakdown Data by Application
5.1 Global Long-Acting Injectables Historic Market Size by Application (2019-2024)
5.2 Global Long-Acting Injectables Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Long-Acting Injectables Market Size (2019-2030)
6.2 North America Long-Acting Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Long-Acting Injectables Market Size by Country (2019-2024)
6.4 North America Long-Acting Injectables Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Long-Acting Injectables Market Size (2019-2030)
7.2 Europe Long-Acting Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Long-Acting Injectables Market Size by Country (2019-2024)
7.4 Europe Long-Acting Injectables Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Long-Acting Injectables Market Size (2019-2030)
8.2 Asia-Pacific Long-Acting Injectables Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Long-Acting Injectables Market Size by Region (2019-2024)
8.4 Asia-Pacific Long-Acting Injectables Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Long-Acting Injectables Market Size (2019-2030)
9.2 Latin America Long-Acting Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Long-Acting Injectables Market Size by Country (2019-2024)
9.4 Latin America Long-Acting Injectables Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Long-Acting Injectables Market Size (2019-2030)
10.2 Middle East & Africa Long-Acting Injectables Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Long-Acting Injectables Market Size by Country (2019-2024)
10.4 Middle East & Africa Long-Acting Injectables Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Long-Acting Injectables Introduction
11.1.4 Eli Lilly Revenue in Long-Acting Injectables Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Long-Acting Injectables Introduction
11.2.4 Pfizer Revenue in Long-Acting Injectables Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Detail
11.3.2 GlaxoSmithKline Business Overview
11.3.3 GlaxoSmithKline Long-Acting Injectables Introduction
11.3.4 GlaxoSmithKline Revenue in Long-Acting Injectables Business (2019-2024)
11.3.5 GlaxoSmithKline Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Long-Acting Injectables Introduction
11.4.4 Johnson & Johnson Revenue in Long-Acting Injectables Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Lupin
11.5.1 Lupin Company Detail
11.5.2 Lupin Business Overview
11.5.3 Lupin Long-Acting Injectables Introduction
11.5.4 Lupin Revenue in Long-Acting Injectables Business (2019-2024)
11.5.5 Lupin Recent Development
11.6 Zogenix
11.6.1 Zogenix Company Detail
11.6.2 Zogenix Business Overview
11.6.3 Zogenix Long-Acting Injectables Introduction
11.6.4 Zogenix Revenue in Long-Acting Injectables Business (2019-2024)
11.6.5 Zogenix Recent Development
11.7 DURECT
11.7.1 DURECT Company Detail
11.7.2 DURECT Business Overview
11.7.3 DURECT Long-Acting Injectables Introduction
11.7.4 DURECT Revenue in Long-Acting Injectables Business (2019-2024)
11.7.5 DURECT Recent Development
11.8 Medincel
11.8.1 Medincel Company Detail
11.8.2 Medincel Business Overview
11.8.3 Medincel Long-Acting Injectables Introduction
11.8.4 Medincel Revenue in Long-Acting Injectables Business (2019-2024)
11.8.5 Medincel Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
